Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Cassava Sciences Reports Second Quarter 2021 Financial Results
08:30am, Tuesday, 03'rd Aug 2021
- Conference Call Today at 9 a.m. ET - - Conference Call Today at 9 a.m. ET -
5 Ultra-Popular Stocks to Avoid Like the Plague in August
06:06am, Tuesday, 03'rd Aug 2021
These stocks look to be more trouble than they're worth.
Cassava Sciences Announces Conference Call for Second Quarter Financial Results
07:54pm, Monday, 02'nd Aug 2021
- Call-in on Tuesday, August 3rd at 9 a.m. ET - - Call-in on Tuesday, August 3rd at 9 a.m. ET -
Cassava Sciences' Simufilam Is The First Alzheimer's Drug To Work At 9 Months, And The Benefit Is Growing
09:47am, Friday, 30'th Jul 2021
Simufilam is the first AD drug to show a cognitive improvement at 9 months, with a gaudy 18% mean improvement from baseline. Simufilam also showed a growing behavioral benefit.
SAVA Stock Fell 23.61%: Details You Should Know
05:39pm, Thursday, 29'th Jul 2021
The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 25% during intraday trading. These are some details you should know.
Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data
05:08pm, Thursday, 29'th Jul 2021
As Cassava Sciences made progress in treating Alzheimer's, SAVA stock is on a powerful path to significantly higher prices. The post Cassava Sciences Stock Has Plenty of Momentum After Positive Clinic
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
03:30pm, Thursday, 29'th Jul 2021
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
07:32am, Thursday, 29'th Jul 2021
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease.
Cassava Sciences: Critical Alzheimer's Data Due Thursday Offers Upside Potential
04:24pm, Tuesday, 27'th Jul 2021
Cassava Sciences shares are +3,300% in the past year, but the upside could continue until the $4.5bn market cap biotech achieves a >$50bn valuation.
Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer's Results
04:53pm, Friday, 23'rd Jul 2021
Cassava Sciences stock could jump with its upcoming Alzheimer's results. SAVA stock options show the lofty expectations investors have.
Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment.
Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis
03:23pm, Thursday, 22'nd Jul 2021
On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14, 2000 and December of that year
Cassava Sciences stock price forecast for Q3 after shares rally 27%
05:23pm, Wednesday, 21'st Jul 2021
Meme stock Cassava Sciences Inc. (NASDAQ:SAVA) shares surged more than 27% on Wednesday after revealing plans to present data on its Alzheimer's drug, Simufilam, on 29th July. Cassava will read out it
Here's Why Cassava Sciences Is Surging Today
03:39pm, Wednesday, 21'st Jul 2021
Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference.
SAVA Stock: Two Dates Cassava Investors Need to Mark on Their Calendars
01:25pm, Wednesday, 21'st Jul 2021
SAVA stock is flying upward today as investors clamor to hear information around two new products. Investors should save two upcoming dates.
